Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

MLA

Mason, Kayleigh J., et al. “Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.” JAMA Dermatology, vol. 154, no. 5, May 2018, pp. 581–88. EBSCOhost, https://doi.org/10.1001/jamadermatol.2018.0183.

APA

Mason, K. J., Barker, J. N. W. N., Smith, C. H., Hampton, P. J., Lunt, M., McElhone, K., Warren, R. B., Yiu, Z. Z. N., Griffiths, C. E. M., & Burden, A. D. (2018). Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154(5), 581–588. https://doi.org/10.1001/jamadermatol.2018.0183

Chicago

Mason, Kayleigh J, Jonathan N W N Barker, Catherine H Smith, Philip J Hampton, Mark Lunt, Kathleen McElhone, Richard B Warren, Zenas Z N Yiu, Christopher E M Griffiths, and A David Burden. 2018. “Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.” JAMA Dermatology 154 (5): 581–88. doi:10.1001/jamadermatol.2018.0183.